Agree - different paths - same conclusion! It is novel to describe an entirely different mechanism of action in the lead to OA, so Paradigm is adding IP value to the medical community in solving this disease. I have a hunch the upcoming peer reviewed journal is to support the patent claim.
I also note the invention covers the need for MRI scans pre and post treatment. This would serve 2 purposes - to foist upon any competitor trying to use PPS to treat OA to prove the patient doesn’t have BME (ie MRI scans have to be undertaken). I would also think MRI scans will be part of the treatment package and will bolster the $1500-$2500 price tag.
Paradigm Ip Patents/ Trademarks, page-27
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
-0.015(6.38%) |
Mkt cap ! $76.95M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 23.5¢ | 22.0¢ | $116.8K | 504.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 166525 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 87212 | 5 |
View Market Depth
| Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |